Growth-hormone axis · Peptide
Sermorelin
Also known as GHRH 1-29
Prompts the body's own growth-hormone release in a natural, pulsed way.
Status as of 2026-07 · reclassification ≠ FDA approval · educational only, not medical advice.
The signal it sends
A GHRH analog acting on the pituitary gland.
Benefits & effects studied
- Lean mass & recovery support
- May aid sleep
- Gentler than synthetic GH
Research state
Long clinical history as a GH-stimulation test/therapy.
Dosing & pharmacokinetics
Nightly subcutaneous injection in protocols. Half-life: ~10–20 minutes (nightly dosing).
Dosing information is educational only. Sermorelin decisions belong with a licensed clinician — Jevity does not recommend or supply dosing.
History & discovery
First described early 1980s by Not well documented (multiple groups characterized GRF in the early 1980s; later marketed by Serono) Origin: Emerged after several groups isolated and characterized growth-hormone-releasing factor (GRF) in the early 1980s and found its full activity resided in the first 29 amino acids; FDA-approved in 1997 as Geref (Serono)..
Molecular structure
A synthetic peptide corresponding to the first 29 amino acids of human GHRH (GHRH 1-29 amide).
Frequently asked questions
Is Sermorelin FDA-approved?
Approval withdrawn (non-safety); available compounded (503A) On Jevity's evidence scale, Sermorelin is graded "In human trials". Reclassification for compounding is not the same as FDA approval.
What is Sermorelin used for?
Prompts the body's own growth-hormone release in a natural, pulsed way. A GHRH analog acting on the pituitary gland. Studied effects include: Lean mass & recovery support; May aid sleep; Gentler than synthetic GH. This is educational information, not a recommendation to use it.
Is Sermorelin legal in the UAE?
UAE / DHA status: Prescription-only via a DHA-licensed clinic
Is Sermorelin banned in sport?
WADA status: Prohibited at all times (GH axis)
What is Sermorelin's Jevity Score?
Sermorelin has a Jevity Score of 68/100 — a proprietary composite of evidence strength (7/10), regulatory clarity (7/10) and supply verifiability (6/10). It reflects how established and legitimate the compound is, not a recommendation.
Related growth-hormone axis peptides
Educational information only — not medical advice, a diagnosis, or a recommendation to use any substance or therapy. Regulatory status changes; verify current rules and any personal decision with a licensed clinician. Jevity is operated by Upcapital Global FZCO, Dubai, UAE.